A healthy volunteer study to asses the safety, tolerability and blood levels of AUT00206 tablets
- Conditions
- Phase 1 study in healthy volunteers of a treatment to improve and/or normalize symptoms and deficits in patients with Fragile X Syndrome (FXS)Not Applicable
- Registration Number
- ISRCTN80267019
- Lead Sponsor
- Autifony Therapeutics (United Kingdom)
- Brief Summary
2022 Funder report results see attached file 40474 Funder report V1 04Oct2022.pdf [1] (added 14/11/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 41
Current participant inclusion criteria as of 21/01/2022:
1. Healthy male volunteer (Parts A1 and B only) or healthy female volunteer (Part A2 only).
2. Aged 18 - 45 years (at [first] dosing) (Part A and Part B Groups 1 and 2) or aged >18 years and targeted towards those aged >45 years (Part B Groups 3 and 4)
3. A BMI (Quetelet index) in the range 18.0 - 31.0 kg/m²
4. Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
5. Willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate.
6. Agree to follow the contraception requirements of the trial as described in the protocol/ICF.
7. Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication.
8. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS).
Previous participant inclusion criteria:
1. Healthy male volunteer (Parts A1 and B only) or healthy female volunteer (Part A2 only).
2. Aged 18 - 45 years (at [first] dosing).
3. A BMI (Quetelet index) in the range 18.0 - 31.0 kg/m²
4. Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
5. Willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate.
6. Agree to follow the contraception requirements of the trial as described in the protocol/ICF.
7. Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication.
8. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS).
1. Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and not using a highly-effective method of contraception.
2. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.
3. Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer’s participation in the trial or make it unnecessarily hazardous.
4. Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, post-COVID-19 syndrome (‘long COVID’), or history of any psychotic mental illness.
5. Surgery (eg stomach bypass) or medical condition that might affect absorption of medicines.
6. Presence or history of severe adverse reaction to any drug, or a history of sensitivity to AUT00206 or its excipients.
7. Use of a prescription medicine (except oral contraceptives in females) during the 30 days before the first dose of trial medication, or use of an over-the-counter medicine, with the exception of acetaminophen (paracetamol), during the 7 days before the first dose of trial medication.
8. Use of vaccine (including COVID-19 vaccine) during the 7 days, before first receipt of trial medication until the end of the study.
9. History of epilepsy or seizures.
10. Receipt of an investigational product (including prescription medicines) as part of another clinical trial within the 3 months before [first] admission to this study; in the follow-up period of another clinical trial at the time of screening for this study.
11. Presence or history of drug or alcohol abuse, or intake of more than 14 units of alcohol weekly.
12. Smoking of more than 5 cigarettes daily.
13. Blood pressure and heart rate in supine position at the screening examination outside the ranges: blood pressure 90–140 mm Hg systolic, 40–90 mm Hg diastolic; heart rate 40–100 beats/min.
14. QT value, measured at screening visit, greater than 450 msec (men) or 470 msec (women) on 12-lead ECG, using Fridericia’s formula (QTcF) for correction.
15. Alanine aminotransferase (AST), aspartate aminotransferase (ALT) or alkaline phosphatase (AP) = 1.5 x the upper limit of normal (ULN). A repeat is allowed on one occasion for determination of eligibility.
16. Possibility that the volunteer will not cooperate with the requirements of the protocol.
17. Positive test for hepatitis B, hepatitis C or HIV consistent with ongoing infection.
18. Vegans or people who are on a restricted diet for medical reasons (eg lactose intolerant); or unwilling to eat a high-fat breakfast (Part A1 and A2 only).
19. Positive result for suicidal ideation or behaviour using the C-SSRS, including a positive response to items 3 to 5; or a history of suicidal behaviour in the past year
20. Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood donor.
21. Medical objection by General Practitioner (GP) to volunteer entering trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method